Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Intervals between bone mineral density testing with dual-energy X-ray absorptiometry scans in clinical practice.

Lyu H, Yoshida K, Tedeschi SK, Zhao S, Xu C, Nigwekar SU, Leder BZ, Solomon DH.

Osteoporos Int. 2019 Jan 24. doi: 10.1007/s00198-019-04847-5. [Epub ahead of print]

PMID:
30680429
2.

Medication Prescription Patterns for Secondary Hyperparathyroidism: More Questions than Answers.

Seethapathy H, Nigwekar SU.

Clin J Am Soc Nephrol. 2019 Jan 21. pii: CJN.15081218. doi: 10.2215/CJN.15081218. [Epub ahead of print] No abstract available.

PMID:
30665921
3.

Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease.

Garlo KG, Steele DJR, Nigwekar SU, Chan KE.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):125-136. doi: 10.2215/CJN.06430518. Epub 2018 Dec 28.

PMID:
30593489
4.

Calciphylaxis-as a drug induced adverse event.

Portales-Castillo I, Kroshinsky D, Malhotra CK, Culber-Costley R, Cozzolino MG, Karparis S, Halasz CL, Goverman J, Manley HJ, Malhotra R, Nigwekar SU.

Expert Opin Drug Saf. 2019 Jan;18(1):29-35. doi: 10.1080/14740338.2019.1559813. Epub 2018 Dec 24.

PMID:
30574812
5.

Comparison of denosumab vs. bisphosphonates in osteoporosis patients: A meta-analysis of randomized controlled trials.

Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, Nigwekar SU, Leder BZ, Solomon DH.

J Clin Endocrinol Metab. 2018 Dec 10. doi: 10.1210/jc.2018-02236. [Epub ahead of print]

PMID:
30535289
6.

Sickle Cell Nephropathy in the Pediatric Population.

Olaniran KO, Eneanya ND, Nigwekar SU, Vela-Parada XF, Achebe MM, Sharma A, Thadhani RI.

Blood Purif. 2019;47(1-3):205-213. doi: 10.1159/000494581. Epub 2018 Dec 5. Review.

7.

Palliative Care Use and Patterns of End-of-Life Care in Hospitalized Patients With Calciphylaxis.

Olaniran KO, Percy SG, Zhao S, Blais C, Jackson V, Kamdar MM, Goverman J, Kroshinsky D, Temel JS, Nigwekar SU, Eneanya ND.

J Pain Symptom Manage. 2019 Feb;57(2):e1-e3. doi: 10.1016/j.jpainsymman.2018.10.514. Epub 2018 Nov 3. No abstract available.

PMID:
30399415
8.

Long-Term Anticoagulation for Patients Receiving Dialysis.

Nigwekar SU, Thadhani R.

Circulation. 2018 Oct 9;138(15):1530-1533. doi: 10.1161/CIRCULATIONAHA.118.037091. No abstract available.

PMID:
30354526
9.

Review: update on the management of calciphylaxis.

Seethapathy H, Brandenburg VM, Sinha S, El-Azhary RA, Nigwekar SU.

QJM. 2019 Jan 1;112(1):29-34. doi: 10.1093/qjmed/hcy234. Review.

PMID:
30304522
10.

Factors associated with false-negative pathologic diagnosis of calciphylaxis.

Williams EA, Moy AP, Cipriani NA, Nigwekar SU, Nazarian RM.

J Cutan Pathol. 2019 Jan;46(1):16-25. doi: 10.1111/cup.13364. Epub 2018 Nov 4.

PMID:
30280393
11.

The Successful Use of Apixaban in Dialysis Patients with Calciphylaxis Who Require Anticoagulation: A Retrospective Analysis.

Garza-Mayers AC, Shah R, Sykes DB, Nigwekar SU, Kroshinsky D.

Am J Nephrol. 2018;48(3):168-171. doi: 10.1159/000491881. Epub 2018 Sep 3.

PMID:
30176675
12.

Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.

Allegretti AS, Vela Parada X, Ortiz GA, Long J, Krinsky S, Zhao S, Fuchs BC, Sojoodi M, Zhang D, Karumanchi SA, Kalim S, Nigwekar SU, Thadhani RI, Parikh SM, Chung RT.

Hepatology. 2019 Feb;69(2):729-741. doi: 10.1002/hep.30230. Epub 2019 Jan 4.

PMID:
30141205
13.

Calciphylaxis in Patients With Normal Renal Function: A Case Series and Systematic Review.

Bajaj R, Courbebaisse M, Kroshinsky D, Thadhani RI, Nigwekar SU.

Mayo Clin Proc. 2018 Sep;93(9):1202-1212. doi: 10.1016/j.mayocp.2018.06.001. Epub 2018 Jul 27.

PMID:
30060958
14.

Calciphylaxis.

Nigwekar SU, Thadhani R, Brandenburg VM.

N Engl J Med. 2018 Jul 26;379(4):399-400. doi: 10.1056/NEJMc1807324. No abstract available.

PMID:
30044942
15.

Cutaneous calcification in patients with kidney disease is not always calciphylaxis.

Nigwekar SU, Nazarian RM.

Kidney Int. 2018 Aug;94(2):244-246. doi: 10.1016/j.kint.2018.04.019.

PMID:
30031445
16.

Calciphylaxis.

Nigwekar SU, Thadhani R, Brandenburg VM.

N Engl J Med. 2018 May 3;378(18):1704-1714. doi: 10.1056/NEJMra1505292. Review. No abstract available.

PMID:
29719190
17.

Urinary Stone Disease and Cardiovascular Disease Risk in a Rural Chinese Population.

Fan X, Kalim S, Ye W, Zhao S, Ma J, Nigwekar SU, Chan KE, Cui J, Cai J, Wang L, Heng W, Zhou Y, Sun Y, Cui R, Zhang W, Wang B, Dai Q, Li X, Thadhani R, Li X.

Kidney Int Rep. 2017 Jun 8;2(6):1042-1049. doi: 10.1016/j.ekir.2017.06.001. eCollection 2017 Nov.

18.

Malnutrition-inflammation is a risk factor for cerebral small vessel diseases and cognitive decline in peritoneal dialysis patients: a cross-sectional observational study.

Zheng K, Wang H, Hou B, You H, Yuan J, Luo K, Chen L, Li M, Xu Q, Zhu Y, Cui L, Nigwekar SU, Feng F, Li X.

BMC Nephrol. 2017 Dec 20;18(1):366. doi: 10.1186/s12882-017-0777-1.

19.

Location of skin lesions in Henoch-Sch├Ânlein purpura and its association with significant renal involvement.

St John J, Vedak P, Garza-Mayers AC, Hoang MP, Nigwekar SU, Kroshinsky D.

J Am Acad Dermatol. 2018 Jan;78(1):115-120. doi: 10.1016/j.jaad.2017.04.1122.

PMID:
29241772
20.

Increased Bone Morphogenetic Protein Signaling in the Cutaneous Vasculature of Patients with Calciphylaxis.

Nigwekar SU, Jiramongkolchai P, Wunderer F, Bloch E, Ichinose R, Nazarian RM, Thadhani RI, Malhotra R, Bloch DB.

Am J Nephrol. 2017;46(5):429-438. doi: 10.1159/000484418. Epub 2017 Nov 9.

21.

The prevalence and mortality of hyponatremia is seriously underestimated in Chinese general medical patients: an observational retrospective study.

Hao J, Li Y, Zhang X, Pang C, Wang Y, Nigwekar SU, Qiu L, Chen L.

BMC Nephrol. 2017 Oct 31;18(1):328. doi: 10.1186/s12882-017-0744-x.

22.

Characterization and Correction of Olfactory Deficits in Kidney Disease.

Nigwekar SU, Weiser JM, Kalim S, Xu D, Wibecan JL, Dougherty SM, Mercier-Lafond L, Corapi KM, Eneanya ND, Holbrook EH, Brown D, Thadhani RI, P─âunescu TG.

J Am Soc Nephrol. 2017 Nov;28(11):3395-3403. doi: 10.1681/ASN.2016121308. Epub 2017 Aug 3.

23.

Effectiveness of Self-management Support in Maintenance Haemodialysis Patients with Hypertension: A Pilot Cluster Randomized Controlled Trial.

Huang B, Li Z, Wang Y, Xia J, Shi T, Jiang J, Marie NT, Li X, Nigwekar SU, Chen L.

Nephrology (Carlton). 2017 Jun 30. doi: 10.1111/nep.13098. [Epub ahead of print]

PMID:
28666310
24.

Calciphylaxis.

Nigwekar SU.

Curr Opin Nephrol Hypertens. 2017 Jul;26(4):276-281. doi: 10.1097/MNH.0000000000000328. Review.

25.

Vitamin K-Dependent Carboxylation of Matrix Gla Protein Influences the Risk of Calciphylaxis.

Nigwekar SU, Bloch DB, Nazarian RM, Vermeer C, Booth SL, Xu D, Thadhani RI, Malhotra R.

J Am Soc Nephrol. 2017 Jun;28(6):1717-1722. doi: 10.1681/ASN.2016060651. Epub 2017 Jan 3.

26.

A Nationally Representative Study of Calcific Uremic Arteriolopathy Risk Factors.

Nigwekar SU, Zhao S, Wenger J, Hymes JL, Maddux FW, Thadhani RI, Chan KE.

J Am Soc Nephrol. 2016 Nov;27(11):3421-3429. Epub 2016 Apr 14.

27.

Calciphylaxis in peritoneal dialysis patients: a single center cohort study.

Zhang Y, Corapi KM, Luongo M, Thadhani R, Nigwekar SU.

Int J Nephrol Renovasc Dis. 2016 Sep 19;9:235-241. eCollection 2016.

28.

Interventions for lowering plasma homocysteine levels in dialysis patients.

Nigwekar SU, Kang A, Zoungas S, Cass A, Gallagher MP, Kulshrestha S, Navaneethan SD, Perkovic V, Strippoli GF, Jardine MJ.

Cochrane Database Syst Rev. 2016 May 31;(5):CD004683. doi: 10.1002/14651858.CD004683.pub4. Review.

PMID:
27243372
29.

Mild prolonged chronic hyponatremia and risk of hip fracture in the elderly.

Ayus JC, Fuentes NA, Negri AL, Moritz ML, Giunta DH, Kalantar-Zadeh K, Nigwekar SU, Thadhani RI, Go AS, De Quiros FG.

Nephrol Dial Transplant. 2016 Oct;31(10):1662-9. doi: 10.1093/ndt/gfw029. Epub 2016 Mar 23.

PMID:
27190372
30.

We Do Too Many Parathyroidectomies for Calciphylaxis.

Nigwekar SU, Sprague SM.

Semin Dial. 2016 Jul;29(4):312-4. doi: 10.1111/sdi.12502. Epub 2016 Apr 15.

PMID:
27082830
31.

Optimal management of bone mineral disorders in chronic kidney disease and end stage renal disease.

Lundquist AL, Nigwekar SU.

Curr Opin Nephrol Hypertens. 2016 Mar;25(2):120-6. doi: 10.1097/MNH.0000000000000203. Review.

32.

The Role of Bone Scintigraphy in the Diagnosis of Calciphylaxis.

Paul S, Rabito CA, Vedak P, Nigwekar SU, Kroshinsky D.

JAMA Dermatol. 2017 Jan 1;153(1):101-103. doi: 10.1001/jamadermatol.2015.4591. No abstract available.

PMID:
26677101
33.

Multidisciplinary approach to calcific uremic arteriolopathy.

Nigwekar SU.

Curr Opin Nephrol Hypertens. 2015 Nov;24(6):531-7. doi: 10.1097/MNH.0000000000000175. Review.

PMID:
26371529
34.

Raman spectroscopy for label-free identification of calciphylaxis.

Lloyd WR, Agarwal S, Nigwekar SU, Esmonde-White K, Loder S, Fagan S, Goverman J, Olsen BR, Jumlongras D, Morris MD, Levi B.

J Biomed Opt. 2015 Aug;20(8):80501. doi: 10.1117/1.JBO.20.8.080501.

35.

Calciphylaxis: risk factors, diagnosis, and treatment.

Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, Kamdar MM, Steele DJ, Thadhani RI.

Am J Kidney Dis. 2015 Jul;66(1):133-46. doi: 10.1053/j.ajkd.2015.01.034. Epub 2015 May 7. Review.

36.

Interventions for lowering plasma homocysteine levels in kidney transplant recipients.

Kang A, Nigwekar SU, Perkovic V, Kulshrestha S, Zoungas S, Navaneethan SD, Cass A, Gallagher MP, Ninomiya T, Strippoli GF, Jardine MJ.

Cochrane Database Syst Rev. 2015 May 4;(5):CD007910. doi: 10.1002/14651858.CD007910.pub2. Review.

PMID:
25938479
37.

Nutritional vitamin D supplementation in dialysis: a randomized trial.

Bhan I, Dobens D, Tamez H, Deferio JJ, Li YC, Warren HS, Ankers E, Wenger J, Tucker JK, Trottier C, Pathan F, Kalim S, Nigwekar SU, Thadhani R.

Clin J Am Soc Nephrol. 2015 Apr 7;10(4):611-9. doi: 10.2215/CJN.06910714. Epub 2015 Mar 13.

38.

Quantifying a rare disease in administrative data: the example of calciphylaxis.

Nigwekar SU, Solid CA, Ankers E, Malhotra R, Eggert W, Turchin A, Thadhani RI, Herzog CA.

J Gen Intern Med. 2014 Aug;29 Suppl 3:S724-31. doi: 10.1007/s11606-014-2910-1.

39.

Vitamin D receptor activation: cardiovascular and renal implications.

Nigwekar SU, Thadhani R.

Kidney Int Suppl (2011). 2013 Dec;3(5):427-430. Review.

40.

Calciphylaxis: a rare but fatal delayed complication of Roux-en-Y gastric bypass surgery.

Allegretti AS, Nazarian RM, Goverman J, Nigwekar SU.

Am J Kidney Dis. 2014 Aug;64(2):274-7. doi: 10.1053/j.ajkd.2014.02.029. Epub 2014 Apr 29.

PMID:
24787764
41.

Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD).

Nigwekar SU, Tamez H, Thadhani RI.

Bonekey Rep. 2014 Feb 5;3:498. doi: 10.1038/bonekey.2013.232. eCollection 2014.

42.

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.

Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2014 Jan 28;(1):CD005019. doi: 10.1002/14651858.CD005019.pub4. Review.

PMID:
24470059
43.

HMG CoA reductase inhibitors (statins) for dialysis patients.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, Hegbrant J, Strippoli GF.

Cochrane Database Syst Rev. 2013 Sep 11;(9):CD004289. doi: 10.1002/14651858.CD004289.pub5. Review.

PMID:
24022428
44.

Natriuretic peptides in the management of solid organ transplantation associated acute kidney injury: a systematic review and meta-analysis.

Nigwekar SU, Kulkarni H, Thakar CV.

Int J Nephrol. 2013;2013:949357. doi: 10.1155/2013/949357. Epub 2013 May 16.

45.

Intralesional sodium thiosulfate for the treatment of calciphylaxis.

Strazzula L, Nigwekar SU, Steele D, Tsiaras W, Sise M, Bis S, Smith GP, Kroshinsky D.

JAMA Dermatol. 2013 Aug;149(8):946-9. doi: 10.1001/jamadermatol.2013.4565.

PMID:
23760631
46.

Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study.

Nigwekar SU, Wenger J, Thadhani R, Bhan I.

Am J Kidney Dis. 2013 Oct;62(4):755-62. doi: 10.1053/j.ajkd.2013.02.367. Epub 2013 Apr 13.

47.

Statin use and calcific uremic arteriolopathy: a matched case-control study.

Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R.

Am J Nephrol. 2013;37(4):325-32. doi: 10.1159/000348806. Epub 2013 Mar 21.

48.

Sodium thiosulfate therapy for calcific uremic arteriolopathy.

Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr.

Clin J Am Soc Nephrol. 2013 Jul;8(7):1162-70. doi: 10.2215/CJN.09880912. Epub 2013 Mar 21.

49.

Thyroid hormones for acute kidney injury.

Nigwekar SU, Strippoli GF, Navaneethan SD.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD006740. doi: 10.1002/14651858.CD006740.pub2. Review.

PMID:
23440810
50.

Shining light on vitamin D trials in chronic kidney disease.

Nigwekar SU, Thadhani RI.

Kidney Int. 2013 Feb;83(2):198-200. doi: 10.1038/ki.2012.415.

Supplemental Content

Loading ...
Support Center